The Every Company has raised $55 million in Series D funding to expand production and commercialisation of its precision-fermented egg proteins. The investment, led by McWin Capital Partners via its Food Tech Fund, included contributions from Main Sequence, Bloom8, TO.VC, Minerva Foods, Grosvenor Food & Ag, New Agrarian, and SOSV.
Based in San Francisco, the company produces animal-free egg proteins through precision fermentation, a process that replicates the functionality of traditional eggs without using animal ingredients. Its products are already available through retail, foodservice, and e-commerce channels, and will soon be rolled out in Walmart stores across the United States.
The funding will support manufacturing scale-up and operational growth as Every targets profitability and increased market share within the $270 billion global egg market. The company is focusing on high-volume applications such as bakery and other food manufacturing sectors.
Every’s technology offers a stable supply chain alternative amid challenges in the traditional egg industry, including avian flu outbreaks, feed costs, and market volatility. Its shelf-stable, powdered proteins can be stored for up to 18 months without refrigeration, offering logistical and distribution efficiencies for food producers.